The use of multigene cancer susceptibility panels has revealed that 5% to 10% of women with breast cancer tested for these genes are found to carry a germline pathogenic or likely pathogenic variant (GPV).1,2 As the cost of genetic testing has decreased,3 the pressure to relax genetic testing criteria has increased.4,5 This pressure has only become more insistent now that effective first-line systemic therapies for BRCA1 and BRCA2 heterozygotes with early-stage or metastatic disease have become available.6 The gene discussed is BRCA1; the disease is breast carcinoma.